Vaginal Atrophy News and Research

RSS

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

EMAS clinical guide on low-dose vaginal estrogens for postmenopausal vaginal atrophy

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas.

14 Sep 2012

EMA accepts Pfizer’s bazedoxifene/conjugated estrogens MAA for review

Pfizer Inc. today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.

19 Jul 2012

Bayer receives FDA approval for lower dose formulation of ANGELIQ

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus.

29 Feb 2012

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

IMS launches new Recommendations to manage postmenopausal vaginal atrophy

To mark World Menopause Day on 18th October 2010, the International Menopause Society (IMS) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause.

7 Oct 2010

Big Ow awareness campaign

When it comes to symptoms of menopause like hot flashes, weight gain or trouble sleeping, chances are most women wouldn't hesitate to speak to their doctor. But there is another common - and equally distressing - effect of menopause that many women just keep to themselves. The Big Ow, also known as vaginal atrophy, will affect as many as two million Canadian women in the next 10 years - but most are too shy or embarrassed to talk about it, even with their doctor.

8 Feb 2010

Hormone therapy: An important treatment option for post-menopausal women

In connection with the New York Times’ recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper’s account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.

14 Dec 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

New cream for vaginal dryness approved

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream.

1 Dec 2008

Bionovo discovers new estrogen regulatory elements for breast cancer and osteoporosis drugs

Bionovo Inc. today announced results on the role of estrogen regulatory elements important in developing drugs for breast cancer and osteoporosis.

16 Jun 2008

No apparent increase in coronary heart disease for women who initiate hormone therapy

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE ) , provides comment on a re- analysis of pooled data from both hormone therapy arms of the Women's Health Initiative (WHI) Study published today in the Journal of the American Medical Association.

4 Apr 2007

Ospemifine may also help to prevent breast cancer

A tamoxifen-like drug developed by UC Davis and Finnish researchers, now in clinical testing as a treatment for vaginal atrophy, may also help to prevent breast cancer, two preliminary studies suggest.

3 Nov 2005

Findings from WHI memory study may not directly apply to newly menopausal women

The WHIMS article reported that estrogen therapy does not decrease, but may increase, the risk of probable dementia in women age 65 and older using hormones compared to women taking placebo.

23 Jun 2004